ArticleScientific reports2025
Synthesis, crystal structure, DFT calculations, in-vitro and in-silico studies of novel chromone-isoxazoline conjugates as antibacterial and anti-inflammatory agents.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A quarter-century journey into 4-chromone derivatives: synthesis, reactions, and pioneering applications thereof.RSC advances · 2026Review
- Assessment of antimicrobial activity of [1,2,4]triazolo[4, 3-a]quinoxaline derivatives individually and in combination with levofloxacin.Scientific reports · 2026Article
- Multiscale mechanistic modeling for the rational design of novel dual-target candidates against acetylcholinesterase and NADPH oxidase: an advanced computational study.Frontiers in chemistry · 2026Article
- Regioselective synthesis of novel spiro-isoxazolines congeners as antimicrobial agents:Frontiers in chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In this study, we report the synthesis and biological evaluation of a novel series of chromone-isoxazoline hybrids. These conjugates were successfully synthesized through N-alkylation and 1,3-dipolar cycloaddition reactions, and their structures were determined by spectroscopic analysis (1H and 13C-NMR), mass spectrometry (MS), and X-ray diffraction (XRD) analysis. The XRD study showed that the compound crystallizes in the monoclinic system (S.G: P21/c). The antibacterial activity of the hybrid compounds was assessed in vitro against the Gram-positive bacterium Bacillus subtilis ATCC 6633 and three Gram-negative bacteria (Klebsiella aerogenes ATCC 13,048, Escherichia coli ATCC 27,853, and Salmonella enterica serotype Typhi) using the disk diffusion technique, MIC and MBC assays. The results showed that some tested compounds exhibited promising efficacy compared to the standard antibiotic chloramphenicol, underscoring their potential as antibacterial agents. These results were further validated through the determination of MIC and MBC values using the microdilution test, which showed a strong bactericidal effect of some compounds against the selected bacterial strains. Additionally, the studied compounds showed good anti-inflammatory potential by effectively inhibiting 5-LOX enzyme, with compound 5e was the most active, presenting an IC50 value of 0.951 ± 0.02 mg/mL. These in vitro results were complemented by in silico studies, including ADMET (absorption, distribution, metabolism, excretion, and toxicity) predictions and molecular docking simulations. The docking analyses provided insights into the inhibition mechanisms, revealing specific interactions of the synthesized molecules with target proteins relevant to both their antibacterial and anti-inflammatory activities. Finally, density functional theory (DFT)-based calculations were performed to optimize the geometric structures and analyze the structural and electronic properties of the hybrid compounds. While the results are promising, further optimization of compound potency is necessary to enhance their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.